Type 1 Diabetes

New ADA 2026 analyses show Afrezza delivered comparable glycemic control, favorable safety, and higher treatment satisfaction in youth.

This decision marks the first FDA-approved inhaled insulin for pediatric patients.

A study found no association with prenatal antibiotic use and only a modest, potentially confounded increase in type 1 diabetes risk following early childhood exposure.

FDA approved insulin glargine-aldy as an interchangeable biosimilar to Lantus for type 1 diabetes and adult type 2 diabetes.

FDA expands teplizumab (Tzeld) use to children as young as 1 year with stage 2 type 1 diabetes, aiming to delay progression to clinical disease.

Get caught up with Contemporary Pediatrics. This list helps you navigate our top stories from the week, all in one place.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

A study found that dried blood spot screening can identify presymptomatic type 1 diabetes in children, reducing the risk of diabetic ketoacidosis.

With the priority review, the Prescription Drug User Fee Act date is set for April 29, 2026, for potential approval in this younger indication.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Herbert Bravo, MD, and Marian Rewers, MD, PhD, explored how C-peptide preservation reshaped both clinical management and economic considerations in type 1 diabetes.

Clinicians reviewed evidence linking delayed diagnosis of type 1 diabetes to lasting neurologic and metabolic consequences.

Experts discussed how the 3-stage model reframed type 1 diabetes as a condition that could be detected through earlier screening.

This introductory Special Report episode outlines how advances in staging and early detection are reshaping pediatric approaches to type 1 diabetes.

See the full case of our most recent puzzler quiz, and view the correct diagnosis of this slender teen with a growing abdomen and shrinking height.

A review highlights the benefits and risks of artificial sweeteners in glycemic control, insulin sensitivity, and gut microbiota balance.

Explore groundbreaking therapies for type 1 diabetes that aim to delay onset, preserve β-cell function, and restore insulin independence.

FDA accepts MannKind’s sBLA for Afrezza in children and adolescents with diabetes.

The Phase 3 SURPASS-PEDS trial found tirzepatide improved glycemic control and weight outcomes in youth-onset type 2 diabetes, with benefits lasting one year.

Michael Haller, MD, tell providers they shouldn't be surprised if more children with T1D use inhaled insulin.

Michael Haller, MD, discusses inhaled insulin’s safety, off-label use, and future role in easing type 1 diabetes management for children.

Manufacturer MannKind has submitted a supplemental Biologics Application to the FDA for its inhaled insulin Afrezza.

Most youth with type 1 diabetes in sub-Saharan Africa lack autoimmune markers, suggesting a distinct, non-autoimmune form of insulin-deficient diabetes.

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.